| Dr Dominic Michael Buzzacco, MD | |
|
6655 Post Rd, Dublin, OH 43016-8265 | |
| (614) 339-8500 | |
| Not Available |
| Full Name | Dr Dominic Michael Buzzacco |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 16 Years |
| Location | 6655 Post Rd, Dublin, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1437394947 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 35.099391 (Ohio) | Secondary |
| 207WX0107X | Ophthalmology - Retina Specialist | 35.099391 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Riverside Methodist Hospital | Columbus, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Midwest Retina, Inc | 0244207074 | 9 |
News Archive
New research from Moffitt Cancer Center and its collaborators find that the drug combination rituximab plus lenalidomide was effective and produced long-term responses in patients with mantle cell lymphoma.
Sangamo Therapeutics, Inc. and Pfizer Inc. today announced a collaboration for the development of a potential gene therapy using zinc finger protein transcription factors (ZFP-TFs) to treat amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) linked to mutations of the C9ORF72 gene.
A meta-analysis of clinical trials evaluating the effectiveness of aripiprazole for the treatment of Tourette's disorder (TD) in children and adolescents showed a significantly greater overall improvement in total tics and tic severity from pretreatment to post-treatment for the aripiprazole compared to the placebo group.
Scientists seeking to harness the healing power of a miniscule signaling molecule that plays a critical role in certain acute and chronic diseases have been awarded a Program Project Grant (PPG) of nearly $10 million by the National Heart, Lung and Blood Institute of the National Institutes of Health.
Alnylam Pharmaceuticals, Inc. has announced that it has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1/2 clinical trial with ALN-AAT, a subcutaneously administered investigational RNAi therapeutic targeting alpha-1 antitrypsin (AAT) for the treatment of AAT deficiency-associated liver disease (alpha-1 liver disease).
› Verified 7 days ago
| Entity Name | Midwest Retina, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699846535 PECOS PAC ID: 0244207074 Enrollment ID: O20040913000354 |
News Archive
New research from Moffitt Cancer Center and its collaborators find that the drug combination rituximab plus lenalidomide was effective and produced long-term responses in patients with mantle cell lymphoma.
Sangamo Therapeutics, Inc. and Pfizer Inc. today announced a collaboration for the development of a potential gene therapy using zinc finger protein transcription factors (ZFP-TFs) to treat amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) linked to mutations of the C9ORF72 gene.
A meta-analysis of clinical trials evaluating the effectiveness of aripiprazole for the treatment of Tourette's disorder (TD) in children and adolescents showed a significantly greater overall improvement in total tics and tic severity from pretreatment to post-treatment for the aripiprazole compared to the placebo group.
Scientists seeking to harness the healing power of a miniscule signaling molecule that plays a critical role in certain acute and chronic diseases have been awarded a Program Project Grant (PPG) of nearly $10 million by the National Heart, Lung and Blood Institute of the National Institutes of Health.
Alnylam Pharmaceuticals, Inc. has announced that it has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1/2 clinical trial with ALN-AAT, a subcutaneously administered investigational RNAi therapeutic targeting alpha-1 antitrypsin (AAT) for the treatment of AAT deficiency-associated liver disease (alpha-1 liver disease).
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Dominic Michael Buzzacco, MD 6655 Post Rd, Dublin, OH 43016-8265 Ph: (614) 339-8500 | Dr Dominic Michael Buzzacco, MD 6655 Post Rd, Dublin, OH 43016-8265 Ph: (614) 339-8500 |
News Archive
New research from Moffitt Cancer Center and its collaborators find that the drug combination rituximab plus lenalidomide was effective and produced long-term responses in patients with mantle cell lymphoma.
Sangamo Therapeutics, Inc. and Pfizer Inc. today announced a collaboration for the development of a potential gene therapy using zinc finger protein transcription factors (ZFP-TFs) to treat amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) linked to mutations of the C9ORF72 gene.
A meta-analysis of clinical trials evaluating the effectiveness of aripiprazole for the treatment of Tourette's disorder (TD) in children and adolescents showed a significantly greater overall improvement in total tics and tic severity from pretreatment to post-treatment for the aripiprazole compared to the placebo group.
Scientists seeking to harness the healing power of a miniscule signaling molecule that plays a critical role in certain acute and chronic diseases have been awarded a Program Project Grant (PPG) of nearly $10 million by the National Heart, Lung and Blood Institute of the National Institutes of Health.
Alnylam Pharmaceuticals, Inc. has announced that it has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1/2 clinical trial with ALN-AAT, a subcutaneously administered investigational RNAi therapeutic targeting alpha-1 antitrypsin (AAT) for the treatment of AAT deficiency-associated liver disease (alpha-1 liver disease).
› Verified 7 days ago
Dr. Rebecca Ann Kuennen, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 6435 Post Rd, Dublin, OH 43016 Phone: 614-293-8116 Fax: 614-685-1941 | |
Dino Daniel Klisovic, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 6655 Post Rd, Dublin, OH 43016 Phone: 614-339-8500 Fax: 614-339-8501 | |
Louis J Chorich Iii, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 6655 Post Rd, Dublin, OH 43016 Phone: 614-339-8500 Fax: 614-339-8501 | |
Dr. Thomas C Litzinger, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 5155 Bradenton Ave., Suite 200, Dublin, OH 43017 Phone: 614-766-2006 Fax: 614-766-4637 | |
Samuel A Gallo, MD Ophthalmology Medicare: May Accept Medicare Assignments Practice Location: 6620 Perimeter Dr, Ste 100, Dublin, OH 43016 Phone: 614-766-5438 Fax: 614-408-8269 | |
Dr. Robert B Chambers, DO Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 6655 Post Rd, Dublin, OH 43016 Phone: 614-339-8500 Fax: 614-339-8501 |